Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CTSO 
Cytosorbents Crp (CTSO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: CTSO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.92
1 Year Target Price $4.92
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.02% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.14M USD | Price to earnings Ratio - | 1Y Target Price 4.92 |
Price to earnings Ratio - | 1Y Target Price 4.92 | ||
Volume (30-day avg) 2 | Beta 1.32 | 52 Weeks Range 0.60 - 1.61 | Updated Date 01/9/2026 |
52 Weeks Range 0.60 - 1.61 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -27.77% | Operating Margin (TTM) -28.07% |
Management Effectiveness
Return on Assets (TTM) -19.01% | Return on Equity (TTM) -93.26% |
Valuation
Trailing PE - | Forward PE 7.73 | Enterprise Value 61867297 | Price to Sales(TTM) 1.14 |
Enterprise Value 61867297 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 1.67 | Enterprise Value to EBITDA -1.92 | Shares Outstanding 62804305 | Shares Floating 54924249 |
Shares Outstanding 62804305 | Shares Floating 54924249 | ||
Percent Insiders 15.6 | Percent Institutions 26.21 |
Upturn AI SWOT
Cytosorbents Crp
Company Overview
History and Background
Cytosorbents Corporation (CTSO) was founded in 2001. It is a critical care immunotherapy company focused on the development and commercialization of blood purification technologies. The company's flagship product, CytoSorbu00ae, is an extracorporeal cytokine adsorber that aims to reduce the 'cytokine storm' associated with severe critical illnesses. Significant milestones include FDA Emergency Use Authorization (EUA) for CytoSorb in treating COVID-19 patients, and its widespread adoption in Europe and other international markets.
Core Business Areas
- Medical Devices: Development, manufacturing, and commercialization of blood purification devices, primarily the CytoSorbu00ae extracorporeal adsorber. This technology is designed to remove inflammatory mediators and other harmful substances from the bloodstream.
- Research and Development: Ongoing investment in research and clinical trials to expand the indications for CytoSorbu00ae and develop next-generation blood purification technologies.
Leadership and Structure
Cytosorbents Corporation is led by a management team with expertise in medical devices, critical care, and business development. The organizational structure is typical for a publicly traded medical device company, with departments for research and development, clinical affairs, regulatory affairs, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Description: An extracorporeal blood purification device designed to reduce cytokine storm and other pro-inflammatory mediators in patients with severe critical illnesses. It is used in various critical care settings, including sepsis, trauma, and severe pneumonia. Competitors include other extracorporeal blood purification technologies and therapies aimed at managing inflammation, such as continuous renal replacement therapy (CRRT) with specific filters and immunomodulatory drugs.
- Market Share Data: Precise market share data for CytoSorbu00ae is not publicly disclosed as a standalone percentage, but the company operates in the growing market for extracorporeal blood purification and sepsis management. Its adoption is significant in Europe.
- Number of Users: Used in over 70 countries globally.
- Product Name: CytoSorbu00ae
- Revenue from Product: CytoSorbu00ae is the company's primary revenue driver.
Market Dynamics
Industry Overview
Cytosorbents operates in the critical care and medical device industry, specifically within the rapidly evolving field of blood purification and sepsis management. The global sepsis market is driven by increasing incidence of sepsis, growing awareness, and advancements in treatment technologies. The demand for innovative solutions to manage severe inflammatory responses is high.
Positioning
Cytosorbents is positioned as a leader in extracorporeal cytokine adsorption. Its primary competitive advantage lies in its proprietary CytoSorbu00ae technology, which directly targets the cytokine storm, a key factor in the progression of severe critical illness. The company has established a strong presence in international markets, particularly Europe, and is working towards broader US market access.
Total Addressable Market (TAM)
The TAM for sepsis management and extracorporeal blood purification is substantial and growing, with estimates varying but generally in the billions of dollars globally. Cytosorbents is positioned to capture a significant portion of this market, particularly in applications where cytokine storm is a major concern. Its current penetration is still relatively early-stage, indicating considerable room for growth.
Upturn SWOT Analysis
Strengths
- Proprietary CytoSorbu00ae technology for cytokine adsorption.
- Established international market presence (Europe).
- Positive clinical outcomes and growing body of evidence.
- FDA Emergency Use Authorization for COVID-19.
- Experienced management team.
Weaknesses
- Limited presence in the US market (seeking FDA approval for broader indications).
- Reliance on a single primary product.
- Potentially high cost of therapy.
- Need for ongoing clinical validation for new indications.
Opportunities
- Expansion of US market access through FDA approvals.
- Development of new indications for CytoSorbu00ae (e.g., ARDS, pancreatitis).
- Partnerships and strategic alliances.
- Advancements in critical care medicine increasing the need for its technology.
- Potential for new product development based on its adsorption platform.
Threats
- Regulatory hurdles and delays in FDA approvals.
- Competition from existing and emerging therapies.
- Reimbursement challenges in different healthcare systems.
- Economic downturns impacting healthcare spending.
- Adverse clinical trial results.
Competitors and Market Share
Key Competitors
- Baxter International Inc. (BAX)
- Fresenius Medical Care AG & Co. KGaA (FMS)
- Edwards Lifesciences Corporation (EW)
Competitive Landscape
Cytosorbents differentiates itself with its specialized cytokine adsorption technology, which is a targeted approach to managing the 'cytokine storm'. Competitors like Baxter and Fresenius offer broader portfolios in dialysis and critical care, including CRRT machines that can be configured for some inflammatory mediator removal. Edwards Lifesciences is a leader in cardiac surgery and critical care monitoring. Cytosorbents' advantage lies in its focused, highly selective adsorption mechanism, though market penetration and broad indication approval remain key challenges against larger, established players.
Growth Trajectory and Initiatives
Historical Growth: Cytosorbents has demonstrated consistent year-over-year revenue growth, particularly in its international markets, driven by increasing adoption of CytoSorbu00ae in critical care settings. The company's growth has been characterized by market penetration and geographic expansion.
Future Projections: Future growth is expected to be driven by successful FDA approvals for new indications in the US, further penetration in existing international markets, and potential development of next-generation products. Analyst projections for revenue growth would be available from financial research platforms.
Recent Initiatives: Key initiatives include pursuing FDA approvals for CytoSorbu00ae in specific indications, expanding its sales and marketing infrastructure, and investing in clinical research to broaden the therapeutic applications of its technology.
Summary
Cytosorbents is a promising critical care immunotherapy company with a unique cytokine adsorption technology, CytoSorbu00ae. It has a strong international presence and is poised for significant growth, especially if it secures US FDA approvals. The company's main challenges are navigating regulatory pathways, competition from larger players, and managing its cash burn. Its success hinges on expanding its product indications and achieving widespread market adoption.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Cytosorbents Corporation Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets
- Market Research Reports (general industry data)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information is based on publicly available data and general industry knowledge. Actual financial performance, market share, and competitive landscapes may vary. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytosorbents Crp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2013-11-07 | CEO & Director Dr. Phillip P. Chan M.D., Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.cytosorbents.com |
Full time employees 149 | Website https://www.cytosorbents.com | ||
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.